Intra-Cellular Therapies, Inc.

NasdaqGS:ITCI Stock Report

Market Cap: US$6.7b

Intra-Cellular Therapies Management

Management criteria checks 3/4

Intra-Cellular Therapies' CEO is Sharon Mates, appointed in May 2002, has a tenure of 21.83 years. total yearly compensation is $9.23M, comprised of 9.2% salary and 90.8% bonuses, including company stock and options. directly owns 1.08% of the company’s shares, worth $73.23M. The average tenure of the management team and the board of directors is 5.5 years and 10.2 years respectively.

Key information

Sharon Mates

Chief executive officer

US$9.2m

Total compensation

CEO salary percentage9.2%
CEO tenure21.8yrs
CEO ownership1.1%
Management average tenure5.5yrs
Board average tenure10.2yrs

Recent management updates

Recent updates

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Mar 17
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Intra-Cellular Therapies Is On Fire

Mar 11

Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'

Feb 11

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

Dec 24
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Nov 11
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Aug 07
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

May 09
Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

Apr 17
After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Jan 31
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Oct 25
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Intra-Cellular Therapies: What Lies Ahead

Sep 20

Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug

Aug 22

Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M

Aug 09

We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Jul 09
We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Intra-Cellular Therapies: A Dramatic Story

Jun 18

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Apr 03
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Intra-Cellular: Not Participating In A Bear Market

Mar 31

Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand

Mar 08

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Dec 24
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Intra-Cellular's Second FDA Win Makes It A Great Long-Term Investment

Dec 21

Intra-Cellular Therapies: A Leader In The Psychiatric Medicine Space

Nov 08

We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Aug 06
We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

We Think The Compensation For Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Looks About Right

Jun 15
We Think The Compensation For Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Looks About Right

Intra-Cellular Therapies (ITCI) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow

Jun 04

FDA accepts Intra-Cellular Therapies' lumateperone applications for bipolar depression

May 03

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Mar 23
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

CEO Compensation Analysis

How has Sharon Mates's remuneration changed compared to Intra-Cellular Therapies's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$140m

Sep 30 2023n/an/a

-US$155m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$228m

Dec 31 2022US$9mUS$849k

-US$256m

Sep 30 2022n/an/a

-US$298m

Jun 30 2022n/an/a

-US$321m

Mar 31 2022n/an/a

-US$304m

Dec 31 2021US$7mUS$794k

-US$284m

Sep 30 2021n/an/a

-US$259m

Jun 30 2021n/an/a

-US$237m

Mar 31 2021n/an/a

-US$232m

Dec 31 2020US$5mUS$767k

-US$227m

Sep 30 2020n/an/a

-US$207m

Jun 30 2020n/an/a

-US$187m

Mar 31 2020n/an/a

-US$160m

Dec 31 2019US$5mUS$745k

-US$148m

Sep 30 2019n/an/a

-US$148m

Jun 30 2019n/an/a

-US$155m

Mar 31 2019n/an/a

-US$154m

Dec 31 2018US$4mUS$723k

-US$155m

Sep 30 2018n/an/a

-US$145m

Jun 30 2018n/an/a

-US$126m

Mar 31 2018n/an/a

-US$106m

Dec 31 2017US$5mUS$702k

-US$98m

Compensation vs Market: Sharon's total compensation ($USD9.23M) is about average for companies of similar size in the US market ($USD7.72M).

Compensation vs Earnings: Sharon's compensation has increased whilst the company is unprofitable.


CEO

Sharon Mates (70 yo)

21.8yrs

Tenure

US$9,232,857

Compensation

Dr. Sharon Mates, Ph.D. co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and was its President until March 19, 2024. She has been Chairman and Chief Executive Officer of Intra-Cellular The...


Leadership Team

NamePositionTenureCompensationOwnership
Sharon Mates
Co-Founder21.8yrsUS$9.23m1.08%
$ 73.2m
Michael Halstead
Presidentno dataUS$3.48m0%
$ 0
Suresh Durgam
Executive VP & Chief Medical Officer5.6yrsUS$3.46m0.020%
$ 1.4m
Mark Neumann
EVP & Chief Commercial Officer5.4yrsUS$3.50m0.031%
$ 2.1m
Robert Davis
Senior VP & Chief Scientific Officer8.3yrsUS$2.13mno data
Juan Sanchez
Vice President of Corporate Communications & Investor Relations10yrsUS$1.38mno data
Karen Sheehy
Senior VP & Chief Compliance Officer4.7yrsno datano data
Michael Olchaskey
Senior VP & Head of Regulatory Affairs5.5yrsno datano data
John Bardi
Senior VP of Market Access5yrsno datano data
Willie Earley
Senior VP & Head of Clinical Development1.9yrsno datano data

5.5yrs

Average Tenure

60yo

Average Age

Experienced Management: ITCI's management team is seasoned and experienced (5.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sharon Mates
Co-Founder10.6yrsUS$9.23m1.08%
$ 73.2m
Rory Riggs
Independent Director10.2yrsUS$741.17k0.10%
$ 6.9m
Robert Van Nostrand
Lead Independent Director10.2yrsUS$774.41k0.0099%
$ 670.2k
Joel Marcus
Independent Director10.6yrsUS$743.26k0.041%
$ 2.8m
Carol Tamminga
Chairman of Medical Advisory Boardno datano datano data
John Kane
Member of Medical Advisory Boardno datano datano data
Jeffrey Lieberman
Member of Medical Advisory Boardno datano datano data
Christoph Correll
Member of Medical Advisory Boardno datano datano data
Donald Goff
Member of Medical Advisory Boardno datano datano data
Eduardo Salas
Independent Director1.9yrsUS$716.63k0%
$ 0

10.2yrs

Average Tenure

70yo

Average Age

Experienced Board: ITCI's board of directors are seasoned and experienced ( 10.2 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.